136 related articles for article (PubMed ID: 37344609)
1. Adverse reactions following MPox (monkeypox) vaccination: An overview from the Dutch and global adverse event reporting systems.
van der Boom M; van Hunsel F
Br J Clin Pharmacol; 2023 Nov; 89(11):3302-3310. PubMed ID: 37344609
[TBL] [Abstract][Full Text] [Related]
2. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
3. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
Front Immunol; 2022; 13():965171. PubMed ID: 36263025
[TBL] [Abstract][Full Text] [Related]
4. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
5. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F
Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
Oosterhuis I; Scholl J; van Puijenbroek E; Kant A; van Hunsel F
Drug Saf; 2023 Jan; 46(1):65-75. PubMed ID: 36350465
[TBL] [Abstract][Full Text] [Related]
7. [Reported adverse events following influenza vaccination].
van Balveren-Slingerland L; Rümke HC; Kant AC
Ned Tijdschr Geneeskd; 2014; 158():A6841. PubMed ID: 24518843
[TBL] [Abstract][Full Text] [Related]
8. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.
Hu Y; Li Q; Lin L; Chen E; Chen Y; Qi X
Clin Vaccine Immunol; 2013 Feb; 20(2):211-7. PubMed ID: 23239804
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
[TBL] [Abstract][Full Text] [Related]
11. Imprecision in vaccine adverse event reporting and a methodological analysis of reporting systems to improve pharmacovigilance and public health.
Inokuma Y; Kneller R
Eur J Clin Pharmacol; 2023 Jul; 79(7):989-1002. PubMed ID: 37249640
[TBL] [Abstract][Full Text] [Related]
12. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.
van Puijenbroek EP; Broos N; van Grootheest K
Drug Saf; 2010 Dec; 33(12):1097-108. PubMed ID: 21077700
[TBL] [Abstract][Full Text] [Related]
13. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
van der Boor SC; Schmitz-de Vries ETJ; Smits D; Scholl JHG; Rolfes L; van Hunsel F
Vaccine; 2023 Jun; 41(29):4319-4326. PubMed ID: 37286408
[TBL] [Abstract][Full Text] [Related]
14. Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021.
Gao D; Dong G; Zhu L; Jia N; Sun B
Hum Vaccin Immunother; 2023 Aug; 19(2):2263225. PubMed ID: 37782096
[TBL] [Abstract][Full Text] [Related]
15. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study.
Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K
Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy.
Scavone C; Di Mauro C; Brusco S; Bertini M; di Mauro G; Rafaniello C; Sportiello L; Rossi F; Capuano A
Expert Opin Drug Saf; 2019 May; 18(5):427-433. PubMed ID: 30907147
[No Abstract] [Full Text] [Related]
17. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.
Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y
Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800
[No Abstract] [Full Text] [Related]
18. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
[TBL] [Abstract][Full Text] [Related]
19. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
20. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
Kant A; Jansen J; van Balveren L; van Hunsel F
Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
